GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JW Pharmaceutical (XKRX:001060) » Definitions » Debt-to-Revenue

JW Pharmaceutical (XKRX:001060) Debt-to-Revenue : 0.21 (As of Mar. 2024)


View and export this data going back to 1976. Start your Free Trial

What is JW Pharmaceutical Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

JW Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩98,533 Mil. JW Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩52,419 Mil. JW Pharmaceutical's annualized Revenue for the quarter that ended in Mar. 2024 was ₩722,374 Mil. JW Pharmaceutical's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.21.


JW Pharmaceutical Debt-to-Revenue Historical Data

The historical data trend for JW Pharmaceutical's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW Pharmaceutical Debt-to-Revenue Chart

JW Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.33 0.40 0.31 0.23

JW Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.30 0.29 0.21 0.21

Competitive Comparison of JW Pharmaceutical's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, JW Pharmaceutical's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW Pharmaceutical's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JW Pharmaceutical's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where JW Pharmaceutical's Debt-to-Revenue falls into.



JW Pharmaceutical Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

JW Pharmaceutical's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(117404.624 + 52875.816) / 748526.708
=0.23

JW Pharmaceutical's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(98533.461 + 52419.333) / 722374.084
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


JW Pharmaceutical Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of JW Pharmaceutical's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


JW Pharmaceutical (XKRX:001060) Business Description

Traded in Other Exchanges
Address
2477, Nambusunhwan-ro, Seocho-gu, KOR
JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.

JW Pharmaceutical (XKRX:001060) Headlines

No Headlines